MLYS
NASDAQMineralys Therapeutics Inc.
$28.50-0.38 (-1.32%)
News25/Ratings9
News · 26 weeks88-6%
2025-10-262026-04-19
Mix5590d
- Insider24(44%)
- SEC Filings21(38%)
- Other7(13%)
- Earnings2(4%)
- Leadership1(2%)
Latest news
25 items- INSIDERSEC Form 4 filed by Rodman David Malcom4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)
- SECSEC Form 144 filed by Mineralys Therapeutics Inc.144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)
- INSIDERSEC Form 4 filed by Rodman David Malcom4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)
- INSIDERSEC Form 4 filed by Congleton Jon4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)
- SECSEC Form 144 filed by Mineralys Therapeutics Inc.144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)
- INSIDERSEC Form 4 filed by Rodman David Malcom4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)
- SECSEC Form 144 filed by Mineralys Therapeutics Inc.144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)
- SECSEC Form 144 filed by Mineralys Therapeutics Inc.144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)
- SECSEC Form 144 filed by Mineralys Therapeutics Inc.144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)
- SECSEC Form DEFA14A filed by Mineralys Therapeutics Inc.DEFA14A - Mineralys Therapeutics, Inc. (0001933414) (Filer)
- SECSEC Form DEF 14A filed by Mineralys Therapeutics Inc.DEF 14A - Mineralys Therapeutics, Inc. (0001933414) (Filer)
- INSIDERSEC Form 4 filed by Congleton Jon4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)
- INSIDERSEC Form 4 filed by Karydas Daphne4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)
- SECSEC Form 144 filed by Mineralys Therapeutics Inc.144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)
- SECSEC Form 144 filed by Mineralys Therapeutics Inc.144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)
- INSIDERSEC Form 4 filed by Ra Capital Management, L.P.4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)
- PRMineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal OfficerRADNOR, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced the appointment of Jeffrey A. Munsie as Chief Legal Officer. "Jeff brings deep life sciences experience across critical stages of growth, from preclinical through commercialization," said Jon Congleton, Chief Executive Officer of Mineralys. "His strategic counsel, strong leadership, and proven track record will be instrumental in strengthening our legal and com
- SECSEC Form 144 filed by Mineralys Therapeutics Inc.144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)
- INSIDERChief Medical Officer Rodman David Malcom sold $10,696 worth of shares (417 units at $25.65) and exercised 417 shares at a strike of $15.44 (SEC Form 4)4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)
- INSIDERChief Medical Officer Rodman David Malcom exercised 14,057 shares at a strike of $7.28 and sold $542,973 worth of shares (20,406 units at $26.61), decreasing direct ownership by 8% to 76,140 units (SEC Form 4)4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)
- PRMineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)RADNOR, Pa., March 16, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today that on March 16, 2026, the Compensation Committee of Mineralys' Board of Directors granted an inducement stock option award covering 27,920 shares and an inducement restricted stock unit award covering 20,940 shares of Mineralys common stock to a new non-executive employee. The awards were granted under Mineralys' 2025 Employment Inducement Incentive Awa
- SECSEC Form 144 filed by Mineralys Therapeutics Inc.144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)
- SECSEC Form 10-K filed by Mineralys Therapeutics Inc.10-K - Mineralys Therapeutics, Inc. (0001933414) (Filer)
- SECSEC Form 144 filed by Mineralys Therapeutics Inc.144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)
- SECMineralys Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Mineralys Therapeutics, Inc. (0001933414) (Filer)